Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
Curtis A. Lachowiez, Nicola Long, Jennifer N. Saultz, et al.
Blood Advances (2022) Vol. 7, Iss. 9, pp. 1899-1909
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
Sandra Huber, Constance Baer, Stephan Hütter, et al.
Leukemia (2023) Vol. 37, Iss. 7, pp. 1413-1420
Open Access | Times Cited: 41
Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Álex Bataller, Alexandre Bazinet, Courtney D. DiNardo, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 927-935
Open Access | Times Cited: 29
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 10
Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system
Haixiao Zhang, Xinhui Zheng, Wenwen Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon, et al.
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4539-4549
Open Access | Times Cited: 20
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3512-3512
Open Access | Times Cited: 16
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 591-602
Open Access | Times Cited: 16
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
Carlos Jiménez‐Vicente, Paola Charry, Sandra Castaño‐Díez, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 256-267
Closed Access | Times Cited: 5
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Joseph G.W. McCarter, David Nemirovsky, Christopher Famulare, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 5000-5013
Open Access | Times Cited: 13
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
Ga‐Young Song, Hyeon-Jong Kim, Tae‐Hyung Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Measurable Residual Disease in Acute Myeloid Leukaemia
Jacqueline Cloos, Angèle Kelder, Dave de Leeuw, et al.
Cambridge University Press eBooks (2025), pp. 174-192
Closed Access
Potential value of immunogenic cell death related-genes in refining European leukemiaNet guidelines classification and predicting the immune infiltration landscape in acute myeloid leukemia
Changqing Jiao, Xiaoyu Ma, Jianling Cui, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Gene Mutation Characteristics and Prognostic Significance in Acute Myeloid Leukemia Patients From Northeast China
Yiyang Shen, Shuang Fu, Xuan Liu, et al.
Human Mutation (2025) Vol. 2025, Iss. 1
Open Access
Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
Saubia Fathima, Ali Alsugair, Rong He, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Revisiting the Role of Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia
Omer Jamy, Garrett Bourne, Todd William Mudd, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 900-900
Open Access
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
Alexandre Bazinet, Álex Bataller, Tapan M. Kadia, et al.
Cancer (2025) Vol. 131, Iss. 6
Closed Access
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Carlos Jiménez‐Vicente, Jordi Esteve, Mónica Baile-González, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Claudia Sargas, Rosa Ayala, María José Larráyoz, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
Enrico Attardi, Arianna Savi, Beatrice Borsellino, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 5122-5131
Open Access | Times Cited: 10
Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia
Tao Yu, Li Wei, Norio Shiba, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 3
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
Peiqi Liang, Yan Xie, Ziyi Liu, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1219-1226
Closed Access | Times Cited: 3
FLT3 targeting in the modern era: from clonal selection to combination therapies
Vanessa E. Kennedy, Catherine C. Smith
International Journal of Hematology (2023) Vol. 120, Iss. 5, pp. 528-540
Open Access | Times Cited: 8
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Abdulrahman Alhajahjeh, Aziz Nazha
Current Hematologic Malignancy Reports (2023) Vol. 19, Iss. 1, pp. 9-17
Closed Access | Times Cited: 7
Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters
Dina N. Laimon, Doaa H. Sakr, Basma Atef, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3519-3533
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top